Gregory H. Pelton
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Gregory H. Pelton has a total of 12 co-authors. Here are the top co-authors by number of shared publications:
D. P. Devanand
Late Life Depression Clinic, The Memory Disorders Center, and The Division of Geriatric Psychiatry, New York State Psychiatric Institute, NY, USA
1 shared publicationDevangere P. Devanand
1 shared publicationHarold A. Sackeim
The College of Physicians and Surgeons of Columbia University, New York, NY, USA
1 shared publicationKaren Bell
1 shared publicationKaren Marder
1 shared publicationKristin Marston
1 shared publication
Latest Publications
- 19 December 2007
- Published by Wiley in International Journal of Geriatric Psychiatry
- Vol. 23 (7) , 670-676
Randomized double‐blind placebo‐controlled donepezil augmentation in antidepressant‐treated elderly patients with depression and cognitive impairment: a pilot study
Objective: To assess combined antidepressant and cognitive enhancer treatment in elderly patients presenting with depression plus cognitive impairment.Methods: Twenty‐three elderly (>50 years old) depressed, cognitively impaired (DEP‐CI) patients participated in a pilot study. We evaluated whether, after 8 weeks of open antidepressant treatment, donepezil HCl (Aricept) would afford added cognitive benefit compared to placebo in a randomized 12‐week trial. A subsample continued in an 8‐month extension phase of open treatment with donepezil. Neuropsychological testing (NPT) was performed and antidepressant response monitored at baseline and the 8, 20, and 52‐week time points.Results: At 8‐weeks, the antidepressant response rate was 61% (14/23). Improvement in SRT immediate recall (SRT‐IR; e.g. episodic verbal memory) was observed in responders compared to non‐responders. During the 12‐week, placebo‐controlled, donepezil add‐on trial, patients on donepezil showed further improvement in SRT‐IR versus patients on placebo. In the open extension phase, patients who continued open donepezil treatment (n = 6) maintained improvement in memory and tended to show an advantage over patients who never received donepezil and were evaluated at the 52‐week time point (n = 6). There were no observed significant donepezil effects on non‐memory cognitive domains.Conclusion: These preliminary findings suggest that addition of a cholinesterase inhibitor (AChEI) following antidepressant medication treatment in elderly Dep‐CI patients may improve cognition, and support the need for a confirmatory, larger randomized placebo‐controlled trial. Copyright © 2007 John Wiley & Sons, Ltd.
- 19 December 2007
- Published by Wiley in International Journal of Geriatric Psychiatry
- Vol. 23 (7) , 670-676
Randomized double‐blind placebo‐controlled donepezil augmentation in antidepressant‐treated elderly patients with depression and cognitive impairment: a pilot study
Objective: To assess combined antidepressant and cognitive enhancer treatment in elderly patients presenting with depression plus cognitive impairment.Methods: Twenty‐three elderly (>50 years old) depressed, cognitively impaired (DEP‐CI) patients participated in a pilot study. We evaluated whether, after 8 weeks of open antidepressant treatment, donepezil HCl (Aricept) would afford added cognitive benefit compared to placebo in a randomized 12‐week trial. A subsample continued in an 8‐month extension phase of open treatment with donepezil. Neuropsychological testing (NPT) was performed and antidepressant response monitored at baseline and the 8, 20, and 52‐week time points.Results: At 8‐weeks, the antidepressant response rate was 61% (14/23). Improvement in SRT immediate recall (SRT‐IR; e.g. episodic verbal memory) was observed in responders compared to non‐responders. During the 12‐week, placebo‐controlled, donepezil add‐on trial, patients on donepezil showed further improvement in SRT‐IR versus patients on placebo. In the open extension phase, patients who continued open donepezil treatment (n = 6) maintained improvement in memory and tended to show an advantage over patients who never received donepezil and were evaluated at the 52‐week time point (n = 6). There were no observed significant donepezil effects on non‐memory cognitive domains.Conclusion: These preliminary findings suggest that addition of a cholinesterase inhibitor (AChEI) following antidepressant medication treatment in elderly Dep‐CI patients may improve cognition, and support the need for a confirmatory, larger randomized placebo‐controlled trial. Copyright © 2007 John Wiley & Sons, Ltd.
- 1 March 2003
- Published by Elsevier in The American Journal of Geriatric Psychiatry
- Vol. 11 (2) , 186-193
Usefulness of Plasma Haloperidol Levels for Monitoring Clinical Efficacy and Side Effects in Alzheimer Patients With Psychosis and Behavioral Dyscontrol
- 1 March 2003
- Published by Elsevier in The American Journal of Geriatric Psychiatry
- Vol. 11 (2) , 186-193
Usefulness of Plasma Haloperidol Levels for Monitoring Clinical Efficacy and Side Effects in Alzheimer Patients With Psychosis and Behavioral Dyscontrol